Performance status (ECOG/KPS), cancer staging, prognostic scores, and chemotherapy dosing.
Predicts probability of additional non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy
Predicts survival in hepatocellular carcinoma patients based on objective measures of liver function (albumin and bilirubin)
Predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis
Determines disease progression and appropriate treatment course for hepatocellular carcinoma (HCC) patients. The BCLC staging system integrates tumor characteristics, liver function status, and performance status to classify patients into five stages (0, A, B, C, D) with specific treatment recommendations for each stage.
Biologically effective dose and equivalent dose in 2-Gy fractions.
Calculates rate of distant brain failure after stereotactic radiosurgery for brain metastasis to predict overall survival
Carboplatin dose by the Calvert formula.
The CARG-TT estimates the risk of severe chemotherapy-related side effects (Grade 3 or greater toxicity) in older cancer patients (age >65). It uses 11 geriatric assessment variables, laboratory values, and patient characteristics to predict chemotherapy toxicity risk.
BSA-based chemotherapy dosing using Du Bois formula.
Identifies febrile neutropenia patients at low risk for serious complications. Used for adult outpatients with solid tumor, fever ≥38°C (100.4°F), and neutropenia (≤500 cells/mm³ or ≤1,000 cells/mm³ with expected decrease to 500).
Assesses the risk of severe chemotherapy toxicity in older cancer patients (≥70 years). Predicts both hematologic (grade 4) and nonhematologic (grade 3/4) toxicities based on patient characteristics and chemotherapy regimen.
Assesses severity of cytokine release syndrome in immunotherapy patients, particularly those receiving CAR-T cell therapy and other immune effector cell therapies. CRS is an acute inflammatory process marked by a spectrum of clinical symptoms and substantial elevations of serum cytokines.
Grades severity of hematologic and lymphatic adverse events from cancer treatment using standardized criteria. Assesses anemia, neutropenia, thrombocytopenia, and other blood disorders according to laboratory values and clinical presentations.
Assesses 5-year risk of treatment failure in patients with localized prostate cancer based on clinical factors. Stratifies patients into low, intermediate, or high-risk groups to guide treatment decisions and prognosis estimation.
Predicts small-cell lung cancer (SCLC) in patients with Lambert-Eaton myasthenic syndrome (LEMS) using clinical parameters assessed at or within 3 months of onset. The score helps identify high-risk patients requiring intensive cancer screening.
Pre-transplant risk score for allogeneic HSCT (0-7).
Bidirectional conversion between ECOG and Karnofsky scales.
Determines patient's ability to tolerate therapies in severe illness, specifically for chemotherapy. Simple 5-point scale that describes patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability.
CML long-term survival risk score.
Converts a radiotherapy schedule to equivalent dose in 2 Gy fractions.
Predicts recurrence and survival risk for colorectal cancer patients with liver metastases after hepatic resection. Developed from analysis of 1,001 consecutive cases to identify high-risk patients who may benefit from adjuvant therapy or closer surveillance.
Estimates risk for breast cancer based on demographic and clinical data. The Gail Model calculates a woman's absolute risk of developing invasive breast cancer over the next 5 years and up to age 90 (lifetime risk) using personal medical and reproductive history and family history of breast cancer among first-degree relatives.
Diagnoses HCC based on serum biomarkers in patients with chronic liver disease (CLD). The GALAD model combines Gender, Age, AFP-L3, AFP, and DCP (des-gamma-carboxy prothrombin) to provide superior diagnostic accuracy compared to individual biomarkers.
Estimates survival in patients with gastrointestinal cancers and brain metastases. Uses 4 prognostic factors to provide risk stratification and guide treatment decisions for patients with brain metastases from GI cancers.
Inflammation and nutrition-based prognostic score for cancer patients using serum C-reactive protein and albumin levels. Predicts overall survival and disease-free survival across multiple cancer types including colorectal, hepatocellular carcinoma, sarcoma, and lung cancer.
Predicts survival in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapy and assists in treatment selection based on risk stratification
Grades severity of hyperglycemia secondary to immune checkpoint inhibitor therapy and provides management recommendations
Grades severity of hypothyroidism secondary to immune checkpoint inhibitor therapy and provides management recommendations
Grades severity of colitis secondary to immune checkpoint inhibitor therapy and provides management recommendations
Grades severity of hepatitis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates liver function tests including AST, ALT, and total bilirubin levels to determine the severity of immune-mediated hepatitis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, hepatology consultation needs, and monitoring for life-threatening complications. ICPi-induced hepatitis has an incidence of 5-10% in single-agent therapy but severe toxicity occurs in less than 2% of cases. The calculator provides evidence-based management recommendations essential for oncologists, hepatologists, and multidisciplinary teams managing patients on immunotherapy.
Grades severity of pneumonitis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates respiratory symptoms, oxygen requirements, and functional impact to determine the severity of immune-mediated pneumonitis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, pulmonology consultation needs, and monitoring for life-threatening respiratory complications. ICPi-induced pneumonitis has an incidence of 2.7% for all-grade and 0.8% for high-grade pneumonitis in single-agent therapy. The calculator provides evidence-based management recommendations essential for oncologists, pulmonologists, and intensive care teams managing patients on immunotherapy.
Grades severity of nephritis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates serum creatinine levels, renal function changes, and clinical symptoms to determine the severity of immune-mediated nephritis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, nephrology consultation needs, and monitoring for life-threatening renal complications. ICPi-induced nephritis has an incidence of 1-2% in single-agent therapy and 4.5% in combination therapy, with median onset at 14 weeks (range 6.5-21 weeks). The calculator provides evidence-based management recommendations essential for oncologists, nephrologists, and multidisciplinary teams managing patients on immunotherapy.
Simplified iRECIST response classification for solid tumors on immunotherapy.
Determines patient's ability to tolerate therapies in serious illness, specifically for chemotherapy. This validated functional status scale ranges from 100% (normal, no evidence of disease) to 0% (death) and correlates with treatment tolerance, survival, and quality of life in cancer patients.
Predicts VTE risk for cancer patients depending on cancer type and other factors. This validated risk assessment tool helps identify cancer patients at high risk for venous thromboembolism who may benefit from thromboprophylaxis during chemotherapy treatment.
Predicts progression-free and cancer-specific survival in patients with renal cell carcinoma (RCC) using clinical, surgical, and pathologic factors
Predicts survival in patients with malignant pleural effusion using clinical and laboratory parameters to help inform treatment decisions and prognosis discussions
IASLC 8th edition TNM stage grouping for non-small cell lung cancer.
Predicts survival of metastatic renal cell carcinoma, more accurately than the original Motzer Score by incorporating additional prognostic factors
Predicts 3 and 5-year survival after liver transplantation for patients with hepatocellular carcinoma (HCC), especially those not meeting Milan Criteria. Uses tumor size, number, and vascular invasion status.
Predicts risk of pathologic fracture in patients with long bone metastasis to guide prophylactic fixation decisions
Provides improved cancer prognosis over the original Glasgow Prognostic Score, based on serum biomarkers (CRP and albumin) reflecting systemic inflammation and nutritional status
Assesses treatment response in hepatocellular carcinoma (HCC) patients based on viable tumor enhancement, specifically designed for patients receiving targeted therapies and locoregional treatments.
Predicts survival based on clinical and laboratory data in metastatic RCC patients
CTCAE neutropenia grading from the absolute neutrophil count (ANC): Grade 1 (<LLN-1500), Grade 2 (<1500-1000), Grade 3 (<1000-500), Grade 4 (<500 /mm³). Standard oncology toxicity grading for chemotherapy decisions and growth-factor support.
Nottingham Prognostic Index (Haybittle 1982) for primary breast cancer: NPI = 0.2 × tumor size (cm) + lymph-node stage (1-3) + histologic grade (1-3). Bands: ≤2.4 excellent, 2.41-3.4 good, 3.41-4.4 moderate, 4.41-5.4 poor, >5.4 very poor. Implemented from the published paper (AGPL source repo not copied).
Pack-years quantify lifetime smoking exposure: (cigarettes per day / 20) x years smoked. >=20 pack-years is the USPSTF 2021 lung-cancer screening threshold (ages 50-80).
The PaP score estimates 30-day survival probability in advanced solid-tumor patients from 6 variables (dyspnea, anorexia, KPS, clinician prediction, WBC, lymphocyte %). Total 0-17.5.
Pegfilgrastim (Neulasta) dosing per FDA label: adults 6 mg SC once per chemotherapy cycle, ≥24 hours after cytotoxic chemotherapy and ≥14 days before the next cycle. Pediatric weight bands: <10 kg 0.1 mg/kg, 10-20 kg 1.5 mg, 21-30 kg 2.5 mg, 31-44 kg 4 mg, ≥45 kg 6 mg.
Peritoneal Cancer Index (Sugarbaker): 13 abdominopelvic regions each scored by largest lesion — LS-0 none, LS-1 <0.5 cm, LS-2 0.5-5 cm, LS-3 >5 cm or confluence; total 0-39. Higher = greater tumor burden; guides cytoreduction/HIPEC decisions.
Total lesion glycolysis: metabolic tumor volume multiplied by mean SUV. Prognostic PET metric in oncology.
Predicts cancer mortality from serum biomarkers using C-reactive protein (CRP) and white blood cell (WBC) count. This simple two-parameter scoring system provides risk stratification for cancer patients and helps guide prognostic discussions and clinical decision-making across multiple cancer types.
Predicts 3-month mortality in patients with malignant pleural effusion using clinical and biological parameters. This validated prognostic tool combines patient characteristics, performance status, laboratory values, and treatment history to provide accurate risk stratification and guide clinical decision-making for patients with malignant pleural effusion.
Calculates prostate volume using ellipsoid formula and PSA density to help distinguish between benign prostatic hyperplasia (BPH) and prostate cancer. This tool assists in biopsy decision-making, risk stratification, and treatment planning for patients with elevated PSA levels.
Calculates PSA doubling rate in prostate cancer patients with biochemical recurrence after treatment. This prognostic tool correlates with survival and helps guide treatment decisions for salvage therapy, imaging studies, and castration-resistant disease management. Uses longitudinal PSA measurements to determine the rate of PSA increase over time.
Revised International Staging System for multiple myeloma.
QUANTEC-based lung dose constraint check: mean lung dose and V20 vs symptomatic pneumonitis risk.
Spinal Instability Neoplastic Score (SINS): quantifies spinal instability in patients with spinal metastases across 6 components (location, pain, bone lesion, alignment, vertebral collapse, posterolateral involvement). Total 0-18; higher scores indicate greater instability and need for surgical consultation.
UCSF Cancer of the Prostate Risk Assessment (CAPRA, Cooperberg 2005): 0-10 point preoperative score predicting prostate cancer recurrence/ progression risk from PSA, Gleason pattern, clinical stage, age, and percent positive biopsy cores. 0-2 low, 3-5 intermediate, 6-10 high risk.
Clinical Decision Support (CDS) Notice & Legal Disclaimer
All calculations and clinical scoring tools in this directory are intended strictly for educational and decision-support use by licensed medical practitioners. They do not constitute autonomous medical advice or direct treatment orders. See the full DexaMed Medical Disclaimer.